Andrew Penkethman – Managing Director and CEO – Ardea Resources (ASX:ARL) is advancing its flagship 100%-owned Kalgoorlie Nickel Project (KNP). KNP is the largest Nickel–Cobalt resource in Australia and in the top 10 globally, making it of a scale that is incredibly rare and important in the World’s journey to Net Zero. KNP was awarded Major Project Status by the Australian Federal Government, recognising the national and strategic significance of the KNP to the Australian economy and the Eastern Goldfields of Western Australia.
Copyright 2024 – Finance News Network
10 Oct 2023 - Tara French - Managing Director - Cazaly Resources (ASX:CAZ) is a Perth based Australian diversified mineral exploration and resource development company.
04 Oct 2022 - Knosys Limited (ASX:KNO) Managing Director John Thompson discusses FY22 highlights, revenue drivers, growth investments, hybrid working tailwinds and the outlook for FY23.
27 Jun 2022 - North Stawell Minerals Limited (ASX:NSM) CEO Russell Krause discusses recent drilling results, plans through the winter months, and outlook.
01 Apr 2022 - Lepidico Limited (ASX:LPD) Managing Director Joe Walsh discusses the progress of the company's Karibib lithium operations and Abu Dhabi processing plant, potential capital raisings and offtake agreements.
22 Jun 2023 - European Metals Holdings (ASX:EMH) Cinovec Project is strategically located in the heart of the growing European EV ecosystem in the northwest of the Czech Republic. Cinovec is a large historic lithium resource, with a clean pathway to underground development. EMH’s 51 per cent JV partner is the national utility CEZ a subsidiary of CEZ Group, which is owned 70 per cent by the Czech Government.
27 Oct 2022 - icetana Limited (ASX:ICE) CEO and Managing Director Matt Macfarlane discusses the company's recent deal with Japanese group Macnica and the launch of a new product.
20 Mar 2023 - Beston Global Food Company Limited (ASX:BFC) CEO Fabrizio Jorge discusses half-year results, the impact of weather on milk supply, lactoferrin pricing, export markets, the recent capital raising, and M&A opportunities.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
